Hikma Ventures

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

O7 Therapy is a digital platform that enhances access to mental health services for Arabic-speaking individuals. Through its innovative mobile app, the company offers online therapy, psycho-educational resources, and group therapy sessions, facilitating a comprehensive therapeutic experience. O7 Therapy also focuses on corporate wellness by providing Employee Wellness Programs tailored for organizations. This unique approach emphasizes the importance of mental health in the workplace by raising awareness, reducing stigma, and creating supportive environments. By integrating cutting-edge technology and artificial intelligence into its services, O7 Therapy aims to empower users on their journey to mental wellness while promoting effective strategies for mental well-being in both individual and organizational contexts.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Altibbi Ltd. is a digital health platform based in Dubai, United Arab Emirates, that connects users with healthcare information and services throughout the Middle East. Founded in 2008, Altibbi offers a comprehensive range of resources, including medical articles, videos, a medical dictionary, and an encyclopedia of medicines. The platform addresses various health topics, such as chronic diseases, allergies, and dental issues, providing users with the knowledge they need to make informed health decisions. In addition to informational resources, Altibbi facilitates access to healthcare by allowing users to book appointments with qualified doctors via video calls and translating medical terminology into Arabic. The platform is accessible 24/7 through its website and mobile applications, enhancing healthcare access and quality for users in the region.

Activ Surgical Inc. is a digital surgery company based in Boston, Massachusetts, dedicated to enhancing surgical procedures through advanced technology. Established in 2014 and originally known as Omniboros Inc., the company specializes in developing a robotic surgery platform that integrates computer vision, artificial intelligence, and robotics. Its flagship product, the Smart Tissue Autonomous Robot (STAR), is designed to improve surgical efficiency, accuracy, and patient outcomes while reducing the risk of unintended complications. Activ Surgical's innovative, patent-protected surgical software facilitates augmented reality-based and AI-driven operations, thereby enhancing surgeons' intra-operative decision-making and fostering safer surgical practices.

NuvoAir AB, established in 2015 and headquartered in Stockholm, Sweden, specializes in remote patient monitoring for chronic heart and lung conditions. The company's core product is Air Next, a home spirometer that tracks lung function. NuvoAir's innovative platform combines this advanced monitoring technology with personalized care from a multidisciplinary team, including pulmonologists and cardiologists. By collaborating with health plans and risk-bearing entities, NuvoAir offers a value-based care model that aims to reduce healthcare costs and improve patient outcomes.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

SeamlessMD is a developer of a digital patient engagement platform focused on improving health outcomes for patients undergoing surgery. The company addresses the challenges of traditional surgical care, which often relies on paper instructions and human memory, by utilizing design, data, and technology to enhance the patient experience. SeamlessMD's platform supports hospitals in engaging patients through remote monitoring and data collection, which helps optimize recovery processes and reduce readmission rates. By collaborating with healthcare providers, SeamlessMD aims to deliver high-quality surgical care while lowering costs, ultimately ensuring patients have a better and more informed journey through their surgical experiences.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. Its platform collects information on medical history, symptoms, current medications, and allergies, applying evidence-based guidelines to provide consumers with prescriptions. By offering healthcare services at a lower cost than typical co-pays, Lemonaid Health strives to make quality medical care more accessible to patients.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

WinterLight Labs Inc. is a Toronto-based company founded in 2015 that specializes in developing a speech-based platform for the detection and monitoring of cognitive and mental diseases, including dementia and Alzheimer's disease. The company's innovative AI technology analyzes natural speech samples to quantify various speech and language patterns, enabling the accurate assessment of cognitive health. By utilizing a brief one-minute speech sample, WinterLight's platform can characterize aspects such as lexical diversity, syntactic complexity, semantic content, and articulation, effectively capturing the speaker's cognitive state. This diagnostic tool has significant applications across clinical trials, long-term care, primary care, and speech-language pathology, facilitating the early detection of cognitive impairment and tracking disease progression.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Click Therapeutics, Inc. is a New York-based company that specializes in the engineering, validation, development, and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012, Click Therapeutics focuses on creating software-based medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, and chronic pain. Its innovative Digital Therapeutics™ can be utilized independently or alongside traditional biomedical treatments, enhancing patient engagement and treatment outcomes. The company's Clickometrics® adaptive data science platform personalizes user experiences to optimize results. Notably, Click's smoking cessation program has successfully launched nationwide, and its leading prescription program is currently undergoing a phase III FDA registration trial for treating Major Depressive Disorder in adults.

Propeller Health is a digital health company focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company offers a mobile platform that includes sensors, mobile apps, analytics, and services designed to support respiratory health management. The Propeller sensor attaches to users' inhalers and syncs wirelessly with their smartphones, tracking medication use, triggers, and symptoms. It provides personalized feedback and educational content based on the user's data. Users can set up medication reminders and alerts, and share their data with physicians and family members through the Propeller community. The platform is HIPAA compliant and stores users' data in a secure cloud infrastructure. Propeller Health collaborates with various healthcare organizations and has been recognized with several awards, including the TEDMED Innovation Showcase and White House Champion of Change. The company was founded by David Van Sickle, Greg Tracy, and Mark Gehring and is based in Wisconsin.

Biolinq Inc. is a San Diego-based company specializing in the development of innovative skin-applied electronic sensors designed to analyze body fluids and deliver health insights. Founded in 2012, Biolinq focuses on creating a digital health platform that facilitates biomonitoring solutions. Its flagship product is a minimally invasive electrochemical biosensor that continuously monitors various biomarkers in interstitial fluid, including glucose, ketones, and lactate. This technology enables diabetic patients to track their blood glucose levels without the discomfort associated with traditional monitoring methods. By providing actionable health information and insights, Biolinq aims to enhance metabolic health and improve the quality of life for individuals managing diabetes.

Prognos Health is a health tech company focused on healthcare analytics, offering a platform called prognosFACTOR. This innovative platform can quickly query billions of lab and health records from over 325 million de-identified patients, providing answers to clinically relevant healthcare questions in a fraction of the time traditionally required. Prognos Health allows clients to access HIPAA-compliant, patient-centric healthcare data through the Prognos Marketplace, facilitating a range of applications such as cohort design, patient journey studies, and health outcomes analysis. The company's clientele includes 25 of the top 30 pharmaceutical manufacturers and three of the top five health payers, highlighting its significant role in empowering precise decision-making throughout the healthcare landscape.

Lemonaid Health is an online telemedicine platform founded in 2013 and headquartered in San Francisco, California. The company aims to enhance the patient experience and optimize clinical care by utilizing advancements in machine learning and artificial intelligence. Its platform collects information on medical history, symptoms, current medications, and allergies, applying evidence-based guidelines to provide consumers with prescriptions. By offering healthcare services at a lower cost than typical co-pays, Lemonaid Health strives to make quality medical care more accessible to patients.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Propeller Health is a digital health company focused on improving the management of chronic respiratory diseases such as asthma and COPD. The company offers a mobile platform that includes sensors, mobile apps, analytics, and services designed to support respiratory health management. The Propeller sensor attaches to users' inhalers and syncs wirelessly with their smartphones, tracking medication use, triggers, and symptoms. It provides personalized feedback and educational content based on the user's data. Users can set up medication reminders and alerts, and share their data with physicians and family members through the Propeller community. The platform is HIPAA compliant and stores users' data in a secure cloud infrastructure. Propeller Health collaborates with various healthcare organizations and has been recognized with several awards, including the TEDMED Innovation Showcase and White House Champion of Change. The company was founded by David Van Sickle, Greg Tracy, and Mark Gehring and is based in Wisconsin.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.